Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea-Reference-Cited by-同舟云学术

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea

Published:2022-11-29 Issue:1 Volume:1 Page:
ISSN:2755-1520
Container-title:JCEM Case Reports
language:en
Short-container-title:

Author:

Kårhus Martin Lund¹^ORCID,Knudsen Elisabeth²,Knop Filip Krag¹³⁴⁵^ORCID

Affiliation:

1. Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen , 2900 Hellerup , Denmark

2. Clinic of Gastroenterology , 3460 Birkerød , Denmark

3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , 2200 Copenhagen , Denmark

4. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen , 2200 Copenhagen , Denmark

5. Steno Diabetes Center Copenhagen , 2730 Herlev , Denmark

Abstract

AbstractBile acid diarrhea (BAD) is a socially debilitating disease. Typical symptoms include loose stools, urgency, and high stool frequency. Recently, we reported the superior efficacy of the glucagon like-peptide 1 receptor agonist (GLP-1RA) liraglutide (administered subcutaneously once daily) in reducing daily bowel movements compared with the traditionally used bile acid sequestrant colesevelam (considered the standard of care). This has generated proposals of testing longer acting and more potent GLP-1RAs for treating BAD. Here, we present a patient with severe BAD who experienced minimal effect of the once-weekly administered GLP-1RA semaglutide, but total remission of BAD symptoms during treatment with liraglutide.

Publisher

The Endocrine Society

Link

https://academic.oup.com/jcemcr/article-pdf/1/1/luac004/49195776/luac004.pdf

Reference9 articles.

1. Efficacy of colesevelam on lowering glycemia and lipids;Aggarwal;J Cardiovasc Pharmacol,2012

2. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide;Kårhus;Gastroenterology,2019

3. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial;Kårhus;Lancet Gastroenterol Hepatol,2022

4. Glucagon-like peptide 1 in health and disease;Andersen;Nat Rev Endocrinol,2018

5. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin;Lingvay;Diabetes Care,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing bile acid diarrhea: aspects of contention;Expert Review of Gastroenterology & Hepatology;2024-09-12

2. Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. Int. J. Mol. Sci. 2024, 25, 1544;International Journal of Molecular Sciences;2024-07-24

3. The Epidemiology of Bile Acid Diarrhea in Denmark [Response to Letter];Clinical Epidemiology;2024-01

4. A case for screening real‐world data for collateral drug benefits: Glucagon‐like peptide 1 receptor agonists and bile acid diarrhea;Pharmacoepidemiology and Drug Safety;2023-08-09